Sarepta Therapeutics Zooms Higher on Early Data Rally Promising
Sarepta Therapeutics surged about 20% after releasing early Phase 1/2 data for SRP-1001 and SRP-1003, signaling poten...
A concise guide on selecting core crypto assets for beginners who plan to buy and hold for the long term.
28,656 articlesSarepta Therapeutics surged about 20% after releasing early Phase 1/2 data for SRP-1001 and SRP-1003, signaling poten...
Realty Income kicks off 2026 with steady cash flow and high occupancy. This guide breaks down the Q1 results, what th...
A midlife couple faces a classic dilemma after selling a home: extinguish debt at 5% or invest the $175,000 cash pile...
A recently retired federal worker demonstrates a disciplined budget that keeps $8,000 per month viable. Through daily...
In a higher-rate environment, CDL continues to deliver a reliable monthly cash stream with a $2.29 per-share annual d...
Gen X savers still trail target retirement balances, but new guidance shows practical steps—like catch-up contributio...
In early 2026, investigators flagged AI-assisted conversations linked to violent acts, prompting urgent questions abo...
OpenAI and SpaceX confront a profitability horizon that stretches into the 2030s. The classic Good Money framework as...
SpaceX is poised to redefine the IPO window, with investors racing to price in a future where Elon Musk's company goe...
A leading technology analyst questions Intel's current stock value, arguing the market is pricing an AI cycle far int...
RFK Jr. backs a plan to immediately hike payroll taxes to close Social Security's funding gap, triggering political d...
As Alphabet grapples with a recent stock slump, analysts argue the dip may present a tactical buying opportunity amid...